Rigel Pharmaceuticals, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

Cover
- DOCUMENT AND ENTITY INFORMATION
Financial Statements
Notes to Financial Statements
Accounting Policies
- DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
Notes Tables
Notes Details

REVENUES (Tables)

v3.25.0.1

REVENUES (Tables)

12 Months Ended

Dec. 31, 2024

REVENUES

Schedule of revenues disaggregated by category

Revenues disaggregated by category were as follows (in thousands):


	Year Ended December 31,
	2024		2023		2022
Product sales:
Gross product sales	$	209,924	$	147,058	$	108,523
Discounts and allowances		(65,022)		(42,764)		(31,805)
Total product sales, net		144,902		104,294		76,718
Revenues from collaborations:
License revenue		14,000		—		7,932
Milestone revenue		—		75		25,000
Delivery of drug supplies, royalty and others		20,376		11,413		6,092
Total revenues from collaborations		34,376		11,488		39,024
Government contracts		—		1,100		4,500
Total revenues	$	179,278	$	116,882	$	120,242

Schedule of product revenue allowance and reserve categories


	Chargebacks,		Government
	Discounts and		and Other
	Fees		Rebates		Returns		Total
Balance as of January 1, 2024	$	8,236	$	3,517	$	3,931	$	15,684
Provision related to current period sales		49,071		13,586		1,315		63,972
Credit or payments made during the period		(43,933)		(8,760)		(523)		(53,216)
Balance as of December 31, 2024	$	13,374	$	8,343	$	4,723	$	26,440


	Chargebacks,		Government
	Discounts and		and Other
	Fees		Rebates		Returns		Total
Balance as of January 1, 2023	$	6,213	$	2,636	$	3,296	$	12,145
Provision related to current period sales		32,330		8,299		869		41,498
Credit or payments made during the period		(30,307)		(7,418)		(234)		(37,959)
Balance as of December 31, 2023	$	8,236	$	3,517	$	3,931	$	15,684

Customer revenues (as a percentage of gross revenues)


	Year Ended December 31,
	2024		2023		2022
McKesson Corporation		45%		43%		31%
Cencora Inc. (formerly ASD Healthcare)		20%		21%		17%
Cardinal Health, Inc.		13%		25%		19%
Kissei		11%		*		24%

- Definition

The entire disclosure for valuation and qualifying accounts and reserves.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name Regulation S-X (SX)
-Number 210
-Section 12
-Subsection 09
-Publisher SEC

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 4
-Subparagraph (SX 210.12-09)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4

+ Details

Name:	srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock
Namespace Prefix:	srt_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-5

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

- References

No definition available.

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-21

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-20

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-18

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-20

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 16
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-16

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-21

+ Details

Name:	us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration